In the past decade, new strains of methicillin-resistant Staphylococcus aureus (MRSA) have emerged as the predominant cause of community-associated skin and soft-tissue infections (SSTIs) in many areas of North America [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . We have previously reported that MRSA was cultured from the wounds of 59% of 422 adults presenting with acute purulent SSTIs to 11 geographically diverse US emergency departments in 2004 [1] . Pulsed-field type USA300 isolates, which possessed staphylococcal cassette chromosome (SCC) mec type IV and Panton-Valentine leukocidin (PVL) toxin genes, accounted for 97% of MRSA isolates; 74% of these were a single strain, USA300-0114.
Coincident with the emergence of MRSA in community settings, the burden of SSTIs appears to have increased in the United States; between 1993 and 2005, the number of emergency department visits for SSTIs increased .200% [12] . From 2000 to 2004, total hospital admissions for SSTIs increased by 29% [13] .
Although MRSA is resistant to currently available oral b-lactam antibiotics, MRSA strains circulating in the community are typically susceptible to older generic agents. In 2004, we found that rates of susceptibility to trimethoprim-sulfamethoxazole, clindamycin, and tetracycline were 100%, 95%, and 92%, respectively [1] . A Centers for Disease Control and Prevention (CDC)-sponsored experts' meeting summary and an Infectious Diseases Society of America (IDSA) guideline recommended these agents as treatment options for uncomplicated SSTIs in community settings [14, 15] . However, a high prevalence of resistance to clindamycin, tetracycline, and other antimicrobials has recently been described among MRSA USA300 isolates from SSTIs in some community settings in San Francisco and Boston [16] [17] [18] . Also, trimethoprim-sulfamethoxazole resistance has now been observed in a small number of MRSA USA300 isolates [19] . Increasing prevalence of resistance to these antimicrobials would have implications for the selection of empirical therapy.
Infections caused by antibiotic-resistant S. aureus have been described to occur in epidemic waves [20] . For example, the penicillin-resistant S. aureus clone known as phage type 80/81 caused pandemic disease in the 1950s but largely disappeared after methicillin was introduced. Although MRSA has emerged as a community pathogen in many areas of the world, the predominant strains have varied, as has the community prevalence of MRSA. USA300 appears to have rapidly spread across the United States, in some areas replacing other genetic types of MRSA that were previously prevalent. It is unknown whether MRSA USA300 will remain a predominant pathogen and what strains may replace this pulsed-field type.
To assess trends in the prevalence of S. aureus and MRSA as a cause of purulent SSTIs and changes in genetic characteristics and antimicrobial susceptibility profiles of these isolates from such infections, we repeated, in August 2008, a study of adults with purulent SSTIs presenting to our emergency department network that was initially conducted in August 2004, and we compared the findings from these 2 studies [1] .
METHODS
We conducted a prospective prevalence study involving patients 18 years of age or older with a purulent SSTI ,1 week in duration (excluding perirectal abscesses) who presented to hospitals in EMERGEncy ID NET, a network of university-affiliated emergency departments in the following US cities: Albuquerque, New Mexico; Atlanta, Georgia; Baltimore, Maryland; Charlotte, North Carolina; Kansas City, Missouri; Los Angeles, California; Minneapolis, Minnesota; New Orleans, Louisiana; New York, New York; Philadelphia, Pennsylvania; Phoenix, Arizona; and Portland, Oregon. The methods of this study were identical to those of a previous study conducted in August 2004 [1] , except for the following: (1) 1 additional site was included (Baltimore), (2) the study was conducted in August 2008, and (3) patient risk factor insurance, and infection outcome information after emergency department care were not obtained. The number of combined annual visits of the participating emergency departments is approximately 1,000,000. The institutional review board at each site approved the study. Consent was obtained in writing at 6 sites and verbally with an information sheet at 6 sites.
Specimens were processed and cultured at hospital laboratories according to standard techniques. Available S. aureus isolates were forwarded to CDC for characterization. At the CDC, susceptibility to oxacillin, cefoxitin, penicillin, chloramphenicol, erythromycin, clindamycin (constitutive and inducible), daptomycin, tetracycline, doxycycline, gentamicin, levofloxacin, linezolid, mupirocin, rifampin, trimethoprimsulfamethoxazole, and vancomycin was determined by reference broth microdilution [21] . For a small number of the remaining S. aureus isolates, antimicrobial susceptibility test results determined at the hospital clinical laboratories were reported. For all isolates sent to the CDC, the presence of genes encoding staphylococcal toxic shock syndrome toxin 1 (TSST-1; tst) and Panton-Valentine Leukocidin (PVL; lukS-PV) was determined using the LightCycler 480 platform (Roche Diagnostics) via a multiplex PCR assay targeting tst, lukS-PV, nuc (a S. aureusspecific thermonuclease) and mecA (unpublished data; personal communication GEF/BML). Positive, negative, and no template controls were included for each run [BAA-1752 (lukS-PV positive, tst negative, mecA positive, nuc positive), ATCC51650 (lukS-PV negative, tst positive, mecA negative, nuc positive). Extraction of DNA and identification of staphylococcal cassette chromosome (SCCmec) complex was performed according to the methods of Limbago et al [22] . All isolates were typed by PFGE with the use of SmaI restriction endonuclease as previously described [23] .
Descriptive statistics were generated using SAS, version 9.2, to summarize the patient characteristics and prevalence of MRSA. Absolute differences and 95% confidence intervals (95% CI) for differences between proportions were used to compare selected 2004 and 2008 results. The v 2 test for homogeneity was used to test whether MRSA prevalence was similar across sites. Emergency department and laboratory logs for patients with a discharge diagnosis of abscess, cellulitis, or wound infection were reviewed at all study sites to determine the proportion of patients meeting eligibility criteria who were enrolled. Demographic and clinical characteristics of enrolled patients were compared with those of eligible but nonenrolled patients.
RESULTS
A total of 619 patients with a SSTI were enrolled (mean, 52 patients per site) [1] . Patient demographic and infection characteristics were similar to those of the study population in the 2004 study ( Table 1 ). The median age was 39 years, and 58% were men. Infections were classified as an abscess in 85% of patients, an infected wound in 9%, and cellulitis with purulent exudate in 6%. S. aureus was isolated from SSTIs in 463 (75%) patients; 367 (79%) of the S. aureus isolates were methicillin resistant. MRSA was isolated from 59% of SSTIs, including 63% of abscesses, 42% of infected wounds, and 38% of cellulitis with purulent exudate. MRSA was isolated from 331 (62%) of 535 of those subsequently treated as outpatients and 36 (43%) of 84 of those patients who were hospitalized. Methicillin-susceptible S. aureus (MSSA), the next most common pathogen isolated, was found in 96 (16%) of 619 patients. Only 2% of patient specimens grew b-hemolytic streptococci. The prevalence of bacterial isolates at study sites in 2008 is compared with those found in 2004 in Table 2 . The prevalence of MRSA by site ranged from 38% to 84%.
A total of 326 (89%) of the MRSA isolates and 62 (65%) of the MSSA isolates from 12 emergency departments were sent to the CDC for genetic and phenotypic characterization. As observed in 2004, the pulsed-field types of almost all MRSA isolates tested (322 [99%]) were consistent with strains typically causing community-associated MRSA infection: 317 were pulse-field type USA300, 3 were pulsed-field type USA400, and 2 were pulsed-field type USA1000 (3 patients had 2 different MRSA strains). Most USA300 isolates in 2004 and 2008 were a single strain, USA300-0114, or were the closely related USA300-0047. SCCmec type IV and PVL toxin genes were present in almost all MRSA strain.
Among MSSA isolates, USA300 was also the most common pulsed-field type, accounting for 40% of isolates and 56% carried PVL genes. Pulsed-field pattern USA300-0220 accounted for 44% of USA300 MSSA isolates.
MRSA susceptibilities in 2008 were similar to those in 2004, as summarized in Table 3 . Of note, MRSA isolates remained nearly universally susceptible to trimethoprim-sulfamethoxazole (99.7%), and prevalence of susceptibility to clindamycin and tetracycline remained high at 94% and 98%, respectively. Inducible clindamycin resistance was found in 2% (ie, of 295 erythromycin-resistant MRSA isolates, 7 had a positive D-zone disk-diffusion test result). All MRSA isolates were susceptible to vancomycin, linezolid, doxycycline, and daptomycin, and almost all were susceptible to rifampin, chloramphenicol, and gentamicin. Forty-five percent of MRSA isolates were susceptible to levofloxacin, and erythromycin susceptibility remained low at 10%. High-level resistance (minimum inhibitory concentration, .512 lg/mL) to mupirocin was not detected in any S. aureus isolate; the few nonsusceptible isolates demonstrated low-level resistance.
Fourteen percent of 619 patients were hospitalized, and treatment information was available for 615 (99%) of 619 patients. Of 454 patients with an abscess who were treated as outpatients, 76 (17%) received incision and drainage alone, 355 (78%) received incision and drainage and antibiotics, 20 (4%) received antibiotics only, and 3 (0.7%) received neither incision and drainage nor antibiotics (some had draining wounds or were instructed to use warm compresses).
Among patients who received empirical antibiotics, an anti-staphylococcal penicillin or cephalosporin alone was a If a subject reported being Hispanic, they were included in the Hispanic category, even if they also reported being another race/ethnicity.
(46%) of 56 patients in 2004 (absolute difference, 44%; 95% CI, 29%-54%).
Case-finding audits revealed that 30% of eligible patients were enrolled. Compared with enrolled patients, nonenrolled patients were similar in terms of age (median age, 38 y; range, 18-85 y) and sex (56% were male). MRSA was isolated from 86 (50%) of 172 eligible but nonenrolled patients from whom wound cultures were obtained. Similar proportions of eligible (10) 11 (10) 4 (7) 10 (9) Los Angeles, CA 47 36 24 (51) 21 (58) 6 (13) 3 (8) 8 (17) 5 (14) Minneapolis, MN 28 43 11 (39) 17 (40) 4 (14) 10 (23) (56) 11 (16) 3 (11) 9 (13) 6 (22) New York, NY 20 27 3 (15) 12 (44) 8 (40) 11 (41) 5 (25) 1 (4) Philadelphia, PA 58 104 32 (55) 55 (53) 12 (21) 16 (15) 12 (21) 29 (28) Phoenix, AZ 30 89 18 (60) 43 (48) 8 (27) 20 (22) 4 (13) 12 (13) Portland, OR 13 13 7 (54) 5 (38) 2 (15) 2 (15) 3 (23) 2 (15) NOTE. MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus; n/a, not available. a Two patients grew both MRSA and MSSA.
b Other bacteria isolated in 1% or greater of patients were as follows: coagulase-negative Staphylococcus species (6%), b-hemolytic Streptococcus species (2%), viridans Streptococcus species (2%), and Proteus mirabilis (1%).
c P , .001 by the v 2 test for homogeneity of MRSA prevalence across sites. [1] , the prevalence of MRSA has remained stable, accounting for 59% of these infections. We observed less geographic variability in the prevalence of MRSA among study sites in 2008, compared with that in 2004. USA300 strains continue to account for almost all of the MRSA SSTIs identified in this network. Susceptibility of these MRSA strains at these geographically diverse sites remained high to trimethoprim-sulfamethoxazole, clindamycin, and tetracycline despite isolated reports of resistance. Physician empirical prescribing practices dramatically changed, such that b-lactam antibiotics, which were the predominant agents prescribed in 2004, were infrequently used alone in 2008, and were supplanted by MRSA-active antimicrobials.
We are not aware of previously published multicenter data assessing changes in phenotypic and genetic characteristics of S. aureus isolated from SSTIs over the past decade since the widespread emergence of MRSA as a community pathogen. Study sites were emergency departments at large, urban academic centers; our findings may not be fully representative, and populations may have varied between study periods. However, several aspects of these investigations support the validity of longitudinal comparison. The current investigation used an established research network, EMERGEncy ID NET, and applied the same enrollment criteria in 2008 as in 2004. Both studies were conducted in August to control for seasonal changes that might affect colonization and types of trauma. Audits during each study confirmed that enrolled and nonenrolled patients were similar. Although we did not collect insurance and risk factor data in 2008, the population demographic and infection characteristics were similar between the study periods.
Despite the recent observation of a high prevalence of resistance to clindamycin, tetracycline, and mupirocin among USA300 isolates obtained primarily from SSTIs in some US community settings, and isolated reports of trimethoprimsulfamethoxazole resistance in MRSA USA300 isolates, susceptibility to these agents remained high (.90%) at our study sites in 2008. Resistance to several of these agents has been associated with the presence of a conjugative plasmid capable of acquiring multiple resistance elements. Multidrug-resistant USA300 was [16] reported on patients presenting with SSTIs from 1998 through 2005 to a Boston clinic with a large proportion of men who have sex with men and HIV-infected persons. In this study, 48% of MRSA isolates were resistant to clindamycin, and 54% were resistant to tetracycline. Although these studies may reflect unique at-risk populations, a US pediatric clinical trial conducted in St. Louis from 2006 through 2008 also reported an 18% prevalence of resistance to clindamycin among MRSA strains isolated from purulent SSTIs [9] .
In vitro resistance of MRSA of community origin to trimethoprim-sulfamethoxazole also has been observed, although this appears to have remained rare [19] . Among our study sites, no MRSA isolate was resistant to trimethoprim-sulfamethoxazole in 2004, and only 1 (0.2%) of 366 MRSA isolates was resistant in 2008. We did not find high-level resistance to mupirocin, which is a reassuring finding, considering its apparent increasing use for MRSA prophylaxis and the association of mupirocin use with resistance and resistance to decolonization failure [24] .
Between 2004 and 2008, there was a dramatic shift in provider choice of empirical antimicrobial therapy from b-lactam agents, which lack MRSA activity, to MRSA-active drugs. Consequently, there was a substantial reduction in the frequency with which the infecting MRSA isolate was resistant in vitro to the prescribed antimicrobial regimen. By 2008, 90% of patients hospitalized for SSTI received an empirical regimen with MRSA activity, typically vancomycin, although only 43% had MRSA isolated. Rapid molecular staphylococcal testing technologies may result in more appropriate initial antimicrobial treatment, especially because risk factors do not appear to reliably predict MRSA infection [1] .
Consistent with abscess management practices that we observed in 2004, and other surveys [25] , clinicians in our study continued the predominant practice of prescribing antibiotics in addition to performing incision and drainage for patients with infections amenable to outpatient treatment. We are aware of 3 randomized, placebo-controlled trials of patients with a simple abscess conducted after the community emergence of MRSA; these are an adult study using an MRSA-inactive antibiotic, cephalexin, and pediatric and adult studies using trimethoprimsulfamethoxazole [5, 9, 11] . These investigations demonstrated a high cure rate for patients with an uncomplicated abscess with incision and drainage alone (approximately 85%-95%) and no significant difference in cure rate of the primary infection site with the addition of antibiotics. Among patients treated with trimethoprim-sulfamethoxazole in the pediatric and adult studies, the secondary outcome of new lesion rate was lower than that in the placebo group [9, 11] . However, these results should be interpreted with caution because of limitations with baseline study group imbalances, small sample sizes, and patient drop out. Two large National Institutes of Health-funded studies are currently being conducted to further assess the efficacy of antibiotics for simple abscesses.
The prevalence of MRSA USA300 as a cause of purulent SSTIs remains high in many parts of the United States. Over the last few years, clinician-prescribing practices have shifted from MRSA-inactive to MRSA-active empirical antimicrobial regimens. The prevalence of resistance to alternate nonb-lactam therapeutic agents, including trimethoprim-sulfamethoxazole, clindamycin, and tetracyclines, remains low in many US centers; however, in light of the emergence of resistance to these agents in some populations, continued surveillance for local resistance appears to be warranted.
